Wedbush Thinks Xoma Corp’s Stock is Going to Recover


Wedbush analyst Liana Moussatos reiterated a Buy rating on Xoma Corp (XOMA) today and set a price target of $27. The company’s shares opened today at $12.83, close to its 52-week low of $11.02.

According to TipRanks.com, Moussatos is ranked 0 out of 5 stars with an average return of -7.9% and a 34.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.

Xoma Corp has an analyst consensus of Moderate Buy, with a price target consensus of $28.50, representing a 122.1% upside. In a report issued on April 12, H.C. Wainwright also reiterated a Buy rating on the stock with a $30 price target.

See today’s analyst top recommended stocks >>

Based on Xoma Corp’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.01 million. In comparison, last year the company had a GAAP net loss of $3.81 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts